Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

A recent study from National Taiwan University Hospital shows that apixaban, a blood-thinning medication, can help prevent ...

A study shows reduced-dose apixaban effectively prevents recurrent blood clots in cancer patients, lowering bleeding risks ...

Please provide your email address to receive an email when new articles are posted on . Continued anticoagulation is recommended for patients with active cancer and/or ongoing cancer treatment.

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least ...